Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial
Official title:
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Among Patients Attending Neuropsychiatry Department - Assiut University
Chronic dysimmune neuropathies (CDN) are a heterogenous group of acquired inflammatory demyelinating neuropathies including chronic inflammatory demyelinating polyneuropathies (CIDP), Lewis-Sumner Syndrome (LSS), multifocal motor neuropathy (MMN) and other rare entities. Despite their relatively low prevalence, CDN lead to substantial costs for patients and society. CDN are usually misdiagnosed due to progressive nature of the disease with little known data regarding disease activity and treatment response
CIDP is the most common treatable CDN worldwide. Its prevalence is ranging between approximately 1 to 8.9 cases per 100.000 . In addition, there is often the tendency to diagnose CIDP in order to attempt a treatment option. This ultimately leads to overdiagnosis and overtreatment in some patients Although the different CDN have varying underlying pathophysiology and clinical characteristics, they are all potentially treatable with immunomodulatory drugs. To date, diagnostic criteria, measurement of disease activity and treatment response of CDN are mainly based on clinical, electrophysiological, and patient related outcome parameters. The commonly used EFNS/PNS diagnostic criteria for CIDP seems to have the best sensitivity among different sets of diagnostic criteria ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02465359 -
Subcutaneous Immunoglobulin for CIDP
|
N/A | |
| Recruiting |
NCT05584631 -
IVIG vs SCIG in CIDP
|
Phase 1 | |
| Withdrawn |
NCT01236456 -
High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Terminated |
NCT03779828 -
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
|
||
| Completed |
NCT01184846 -
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | |
| Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
| Recruiting |
NCT06290141 -
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
| Completed |
NCT01379833 -
Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
|
||
| Completed |
NCT02414490 -
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
|
||
| Completed |
NCT01545076 -
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
|
Phase 3 | |
| Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
| Recruiting |
NCT04672733 -
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
|
||
| Not yet recruiting |
NCT04480450 -
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Completed |
NCT02111590 -
Immunoglobulin Dosage and Administration Form in CIDP and MMN
|
N/A | |
| Recruiting |
NCT04292834 -
A Registered Cohort Study of Immune-Mediated Neuropathies
|
||
| Terminated |
NCT03772717 -
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
N/A | |
| Completed |
NCT00278629 -
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Recruiting |
NCT02372149 -
IVIg for Demyelination in Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT00962429 -
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 |